Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Marker Therapeutics, Inc. (Nasdaq: MRKR) announced a public offering of its common stock, with underwriters receiving a 30-day option to purchase additional shares. This offering is subject to market conditions and does not guarantee completion or specify terms. Piper Sandler & Co. is the sole book-running manager. The offering follows a shelf registration statement effective since June 25, 2019. Investors can access a preliminary prospectus through the SEC's website. Forward-looking statements about the offering's timing and details are included, reflecting potential risks.
- Public offering aims to raise capital for further development of T cell-based immunotherapies.
- Potential for additional shares to be sold increases financial flexibility.
- Offering may lead to shareholder dilution as new shares are introduced.
- Uncertainty regarding the actual size and terms of the offering may affect investor confidence.
HOUSTON, March 11, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Marker expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. All of the shares to be sold in the offering are to be sold by Marker. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Piper Sandler & Co. is acting as the sole active book-running manager for the offering.
The proposed offering is being made pursuant to a shelf registration statement, including a base prospectus, filed by Marker that was declared effective by the Securities and Exchange Commission ("SEC") on June 25, 2019. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. An electronic copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering will be available on the website of the SEC at www.sec.gov. Copies of the preliminary prospectus supplement, when available, and the accompanying prospectus relating to the offering may be obtained by contacting Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at prospectus@psc.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding the timing, size and completion of the proposed public offering. Forward-looking statements are by their nature subject to risks, uncertainties and other factors that could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Annual Report on Form 10-K and other SEC filings that are available through EDGAR at www.sec.gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
View original content to download multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-inc-announces-proposed-public-offering-of-common-stock-301246042.html
SOURCE Marker Therapeutics, Inc.
FAQ
What is the purpose of Marker Therapeutics' public offering of common stock (MRKR)?
Who is managing the public offering for Marker Therapeutics (MRKR)?
What are the risks associated with Marker Therapeutics' (MRKR) public offering?
When was the shelf registration statement for Marker Therapeutics (MRKR) declared effective?
How can investors obtain the preliminary prospectus for Marker Therapeutics' (MRKR) offering?
